Enterprise Value

626.1M

Cash

354.7M

Avg Qtr Burn

-33.37M

Short % of Float

25.07%

Insider Ownership

1.90%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
JEMPERLI (Dostarlimb-gxly) Details
Solid tumor/s, Cancer, Endometrial cancer

Approved

Quarterly sales

Dostarlimab Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Dostarlimab Details
Ovarian cancer, Cancer

Phase 3

Data readout

Imsidolimab (ANB019) (anti-IL-36R) Details
Ichthyosis, Acne, Hidradenitis suppurativa, EGFRi-mediated skin toxicity, Palmoplantar pustulosis, Generalized pustular psoriasis

Phase 3

Data readout

Rosnilimab (ANB030) (anti-PD-1 agonist) Details
Autoimmune disease, Rheumatoid arthritis

Phase 2b

Data readout

ANB032 (BTLA agonist) Details
Atopic dermatitis

Big Mover™

Susp. Mover™

Phase 2b

Data readout

Phase 2

Data readout

Etokimab (ANB020) Anti-IL-33 Details
Chronic Rhinosinusitis with Nasal Polyps

Failed

Discontinued

Rosnilimab (ANB030) (anti-PD-1 agonist) Details
Alopecia areata, Vitiligo, Skin disease/disorder

Failed

Discontinued